Announcement

Social Media

Meeting Flyer & Brochure

Confirmed Sessions/Speakers as of April 2016

The format of the 15th International Congress on aPL is novel. Prior to the congress, different teams, chaired by the Scientific Planning Committee, will present tentative answers to aPL/APS-related questions derived from evidence-based literature reviews and discussions. These teams will include points of view from different disciplines, e.g., rheumatology, hematology, vascular biology, and immunology.  Each team will consolidate existing knowledge and raise new research ideas for discussion at the congress. The Scientific Planning Committee will also chair sessions on their areas of expertise. The congress will produce a state-of-the-art APS book, entitled “APS – Current Research Highlights and Clinical Insights” to be published in early 2017, which will be available at a discount for congress attendees.

Confirmed Sessions/Speakers as of April 2016 Include:

MAIN SESSION 1 – Origin of Antiphospholipid Antibodies (aPL)

  • General Review – Origin of PL
  • The Role of Innate and Adaptive Immunity in aPL Production
  • Microbiata and Antiphospholipid Syndrome(APS)
  • Are Vaccines Responsible for the Emergence of aPL?



​Joyce Rauch
Rohan Willis
Martin Kriegel
Yehuda Shoenfeld

MAIN SESSION 2 - Mechanisms of aPL-mediated Thrombosis

  • General Review - aPL-mediated Thrombosis
  • The Role of Post-Translational Modification of β2GPI in aPL-mediated Thrombosis
  • Cell Signaling Pathways in aPL-mediated Thrombosis
  • The Role of Coagulation Pathways in aPL-mediated Thrombosis
  • The Central Role of Inflammation in aPL-mediated Thrombosis

Rohan Willis
Steve Krilis

Philip G de Groot
Hannah Cohen

Jason Knight

MAIN SESSION 3 - Mechanisms of aPL-mediated Pregnancy Morbidity

  • General Review - aPL-mediated Pregnancy Morbidity
  • Antiphospholipid Antibody Internalisation into the Syncytiotrophoblast
  • The Role of ApoER2 in aPL-mediated Placental and Endothelial Dysfunction
  • Do Obstetric and Thrombotic aPL Have Differential Effects Upon Target Cells?
  • Targeting β2-Glycoprotein-I to Prevent Obstetric APS

Jane Salmon
Larry Chamley
Chieko Mineo
Ian Giles

Pier Luigi Meroni

MAIN SESSION 4Abstract Recognition Award Presentations

  • A Session In Memory of Silvia Pierangeli and Aziz Gharavi


MAIN SESSION 5 - Definition & Epidemiology of APS

  • Definition of APS
  • Definition of Obstetric APS
  • Antiphospholipid Antibody vs APS
  • Epidemiology of APS


Stephane Zuily
Guilherme De Jesus
Robert Roubey
​​Michael D Lockshin

MAIN SESSION 6 – Pediatric APS: Newborns to Teenagers

  • Developmental Hemostasis
  • Thrombotic and Non-thrombotic Neurological Manifestations in Children With aPL
  • Should We Treat Children with APS Differently?
  • Long-term Follow-up of Children Born to Mothers with APS

Patti Massicotte
Ann Yeh
Gili Kenet
Laura Andreoli

MAIN SESSION 7 - Catastrophic APS: Microangiopathic APS to Thrombotic Storm

  • How Do I Approach Thrombotic Storm?
  • How Do I Approach to Catastrophic APS?

Tom Ortel
Ricard Cervera

MAIN SESSION 8 – Clinical and Prognostic Significance of “Criteria” and Non-Criteria aPL Tests

  • General Overview & “Criteria” ELISA Tests
  • The Significance of IgA Anticardiolipin & Anti-β2-Glycoprotein-I Antibodies
  • Lupus Anticoagulant Assay & Other Tests Relevant to Clinical Practice
  • Anti-phosphatidlyserine/prothrombin Antibodies
  • Anti-Domain I Antibodies – A Specific and Predictive Marker of Thrombosis

Maria Laura Bertolaccini
Angela Tincani
Ian Mackie
Tatsuya Atsumi
Bas de Laat

MAIN SESSION 9- Prevention & Treatment of Thrombotic APS

  • General Review - Primary Thrombosis Prevention
  • General Review – Secondary Thrombosis Prevention
  • Importance of Cardiovascular Disease Prevention in APS
  • Can We Stop Anticoagulation in APS Patients with Previous Thrombosis?
  • Hydroxychloroquine in APS – Where do we stand?

Guillermo Ruiz-Irastorza
Mark Crowther
Ian Bruce

David Garcia
Maria G. Tektonidou

MAIN SESSION 10- Prevention & Treatment of Obstetric Antiphospholipid Syndrome

  • Assessment of Fetal Death - The Role of aPL and Other Confounding Factors
  • What is the Impact of Treatment in Obstetric APS?
  • What is the Role of Hydroxychloroquine in Obstetric APS?

Robert Silver
Ware Branch

Munther Khamashta

MAIN SESSION 11- Management of Non-Criteria Manifestations in APS

  • Antiphospholipid Antibody Nephropathy
  • Severe Thrombocytopenia
     
  • Cardiac Valve Disease
  • Skin Ulcers

Maria G. Tektonidou
Michelle Ugolini &
Reyhan Diz Kucukkaya
TBD & Mary Carmen Amigo
Michelle Ugolini & TBD

MAIN SESSION 12 - Neuropsychiatric APS

  • Antiphospholipid Antibodies & Brain:
    • ​​Neuroimaging Findings
    • Non-vascular Manifestations & Treatment Options
  • Antiphospholipid Antibodies & Cognitive Dysfunction:
    • Potential Mechanisms and the Effect of aPL 
      In Mouse Fetal Brain Development
    • Clinical Perspectives

Simone Appenzeller
Giovanni Sanna


Guillermina Girardi

Elizabeth Kozora

DEEP DIVE SESSION 1- Antiphospholipid Syndrome Treatment Trends Task Force Report*

  • Introduction & Summary of the 2013 Task Force Report
  • Is There a Role for Anti-peptide Therapy in APS?
  • What is New in Anti-complement Therapy in APS?
  • Is mTOR Inhibition an Option in APS?
  • B cell Inhibition in APS – Where do we stand?
  • Statins in APS – Where do we stand?
  • Other Potential Treatment Trends in APS
  • Future Directions

Maria Tektonidou
Anisur Rahman
​Danieli Andrade
Guillaume Canaud
Ricard Cervera
Maria Cuadrado
Maria Gerosa
Danieli Andrade

DEEP DIVE SESSION 2 – Direct Oral Anticoagulants and APS

  • General Review of Direct Oral Anticoagulants (DOACs)
  • RAPS – Rivaroxaban in APS
  • RAPS – Rivaroxaban in APS Pilot Trial Update
  • TRAPS - Rivaroxaban in Thrombotic APS Trial Update
  • ASTRO APS - Apixaban for the Secondary Thromboembolism Prevention in APS

David Garcia
Hannah Cohen

Mark Crowther
Vittorio Pengo

Scott Woller

DEEP DIVE SESSION 3 – International & National Collaborative Research Efforts in APS

  • APS ACTION 6-year Anniversary & “Hydroxychloroquine Trial”
  • Challenges of International Clinical Trials – 
    Contact Research Organization Perspective
  • National Heart Lung and Blood Institute (NHBLI) (NIH) Support of 
    ​International Clinical Trials & Studies
  • Strategies to Recruit Patients for Rare Diseases
  • Update on European Forum on aPL
  • Lessons Learned from a National APS Registry

Doruk Erkan
​Niti Goel

Andrei L. Kindzelski

Oral Alpan
Ricard Cervera

Ljudmila Stojanovich 

DEEP DIVE SESSION 4 - Disease and Risk Measurement Criteria in APS

  • Introduction & the Importance of Disease/Risk Measurement in APS                         
  • Damage Index in APS
  • Antiphospholipid Score: A Quantitative Index for Diagnosis of APS
    & Predictive Marker of Thrombosis
  • GAPSS: The Global APS Score
  • Can We Measure APS Disease Activity?
  • Quality of life in APS

Mary-Carmen Amigo
Victoria Goycochea-Robles


Tatsuya Atsumi
Savino Sciascia
Anisur Rahman
Stephane Zuily

DEEP DIVE SESSION 5 (A Joint Session with ISTH): – Guidelines for aPL Testing

  • Introduction and Overview of ISTH LA Subcommittee Activities
  • Lupus Anticoagulant Testing Guidelines
  • Solid Phase aPL ELISA Testing Guidelines
  • Conclusions and Future Collaboration Opportunities

Bas de Laat
Philip G de Groot
Katrien Devreese

Maria Laura Bertolaccini

DEEP DIVE SESSION 6 – Catastrophic APS (CAPS) Task Force Report*

  • Introduction, Task Force Report, and Future Directions
  • International CAPS Registry Update I: Clinical & Laboratory Characteristics
  • International CAPS Registry Update II: Management
  • Pathogenesis of CAPS – What Do We Know Better?

Ricard Cervera
Ignasi Rodriguez-Pento

Gerard Espinosa
Yehuda Shoenfeld 

DEEP DIVE SESSION 7 – Pediatric APS Task Force Report*

  • Introduction, Task Force Report, and Future Directions
  • Neonatal APS & Beyond: A General Review
  • Pediatric APS Registries: Past, Present, and Future
  • Probing the North American Lupus Registries for APS Data

Barry Myones
Cassyanne Aguiar
Tadej Avcin
Arzu Soybilgic

DEEP DIVE SESSION 8 – Antiphospholipid Syndrome Classification Criteria Task Force Report*

  • Sapporo APS Classification Criteria: Historical Perspective
  • Strengths and Limitations of Updated Sapporo APS Classification Criteria
  • 14th International Congress Task Force Report on “Non-criteria” Manifestations
  • 15th International Congress New APS Classification Criteria Initiative
  • Multi-criteria Decision Analysis & 1000Minds Software for New APS Criteria
  • How Do Meta-analyses Help Us Develop New Classification Criteria?

Takao Koike
Ronald Derksen
Roger Levy

Doruk Erkan
TBD
Denis Wahl

DEEP DIVE SESSION 9 – Natural Proteins Involved in Antiphospholipid Syndrome

  • Introduction & General Review
  • The Structure and Post-Translational Modification of β2-Glycoprotein-I
  • Reimagining APS Through the Door of Imaging: Macro-immune Complexes in APS
  • Small angled X-ray Scattering of β2-Glycoprotein-I
  • Platelet-derived Chemokine & Endothelial Cell Interaction in APS

Philip G de Groot
Steve Krilis
Jacob Rand

Bas de Lat
Panayiotis Vlachoyiannopoulos

DEEP DIVE SESSION 10- New Generation aPL Tests

  • Anti-β2-Glycoprotein-I/HLA Class II Complex Antibodies in APS
  • Anti-Domain IV/V Antibodies in APS
  • Anti-Factor X Antibodies in APS
  • Annexin A5 Resistance Assay & Alternative Functional Assays

Hisashi Arase
Pier Luigi Meroni

Bahar Artim Esen
Jacob Rand

DEEP DIVE SESSION 11 – Interplay Between Lupus and APS

  • Introduction to Overlap Diseases
  • Pathophysiological/Pathogenetic Interplay Between Lupus and APS
  • The Impact of aPL in Lupus
  • What Did We Learn From Hopkins Lupus Cohort About aPL/APS?
  • Debate – Lupus and APS are Different Diseases
  • Debate – Lupus and APS are the Same Disease

Michael D. Lockshin
Pier Luigi Meroni

Murat Inanc
Michelle Petri
Munther Khamashta

Joan Merrill

DEEP DIVE SESSION 12 – Oral Communications

 


*14th International Congress on aPL (September 2013, Rio de Janeiro, Brazil) Task Forces were: a) Laboratory Diagnostics and Trends;
​ b) Obstetric Diagnostics and Treatment; c) Clinical Features; d) Treatment Trends; and e) Catastrophic APS. While two of these Task Forces (Treatment Trends and Catastrophic APS) remain active for the 15th International Congress on aPL, the rest have been merged under a new “Task Force on APS Classification Criteria”. In addition, a Pediatric APS Task Force has been created. Task Force presentations will be incorporated throughout the three-day program.

 
Pre-congress Bosphorus Lupus Lectures (September 21, 2016; no additional fee required; case discussions during lunch; sponsored by an unrestricted educational grant GlaxoSmithKline [GSK])
  • Etiopathogenesis: What is New?

Peggy Crow

  • Clinical Manifestations: What Do We Understand Better?

Michelle Petri

  • Quality of Life I: How to Assess the Impact of Disease?

Paul Fortin

  • Quality of Life II: How to Assess and Prevent CVD?

Ian Bruce

  • Organ Damage: Is it Possible to Prevent Damage?

Mary-Carmen Amigo

  • Treatment I: Present Options & Challenges

Michelle Petri

  • Treatment II: Future Options & Challenges

Joan Merrill

  • Lupus & Pregnancy: Critical Issues and Common Pitfalls

Munther Khamashta

 
Meet the Expert Sessions (no additional fee required; limited space available; selected sessions will also be available in Turkish)​

September 22, 2016 - Thursday AM Sessions (7-8am):
 

 

  • Antiphospholipid Antibody ELISA Tests:
    Technical Aspects and Interpretation

Maria Laura Bertolaccini

  • Antiphospholipid Antibody ELISA Tests:
    Technical Aspects and Interpretation (Turkish)
Bahar Artim Esen

 
  • Lupus Anticoagulant:
    Technical Aspects and Interpretation

Ian Mackie

  • Lupus Anticoagulant:
    Technical Aspects and Interpretation (Turkish)

Reyhan Diz Kucukkaya


September 23, 2016 - Friday AM Sessions (7-8am):
 
  • Difficult-to-treat Antiphospholipid Syndrome
Graham Hughes
  • Difficult-to-treat Antiphospholipid Syndrome (Turkish)

Doruk Erkan

  • Obstetric Antiphospholipid Syndrome
Ware Branch
  • Antiphospholipid Antibodies/Syndrome in Lupus
Paul Fortin

September 23, 2016- Friday Noon Sessions (12.30-1.30pm):
 
  • Obstetric Antiphospholipid Syndrome (Turkish)
Recep Has
  • Antiphospholipid Antibodies/Syndrome in Lupus (Turkish)

Murat Inanc

  • Digital Media for Antiphospholipid Syndrome Education
Laurent Phialy
  • Cardiovascular Imaging in Antiphospholipid Syndrome
Stephane Zuily

September 24, 2016 - Saturday AM Sessions (7-8am):
 
  • Catastrophic Antiphospholipid Syndrome
Ricard Cervera
  • Catastrophic Antiphospholipid Syndrome (Turkish)
Doruk Erkan
  • Pediatric Antiphospholipid Syndrome
Tadej Avcin
  • Pediatric Antiphospholipid Syndrome (Turkish)
Arzu Soybilgic

Please e-mail Dilara Doger @ dilara.doger@serenas.com.tr for
further information and/or to reserve your seat
 
Industry-sponsored Satellite Symposiums (no additional fee required)


September 22, 2016 - Satellite Symposium I – The Future of Antiphospholipid Antibody Testing

  • ​​Organized/Sponsored by Inova Diagnostics & Instrumentation Laboratory
  • Moderators: Maria Laura Bertolaccini and Hannah Cohen
  • The Value of Microparticle Chemiluminescence Technology for Antiphospholipid Antibody Testing - Gabriella Lakos
  • β2-Glycoprotein-I Domain-I in the Assessment of Thrombosis Risk in Antiphospholipid Syndrome - Anisur Rahman
  • Potential for Anti-Phosphatidylserine/Prothrombin Antibodies as a Criteria Test - Maria Laura Bertolaccini
  • Lupus Anticoagulant Test: The Value of Dilute Russell’s Viper Venom Time (dRVVT) and Silica Clotting Time (SCT) Assays - Ian Mackie


September 24, 2016 - Satellite Symposium II Systemic Lupus Erythematosus​​

  • Sponsored by an Unrestricted Educational Grant by GlaxoSmithKline (GSK)
  • Moderators: Doruk Erkan and Murat Inanc
  • What Can Be Learned from Lupus Clinical Trials Applicable to Antiphospholipid Syndrome? Opportunities and Limitations - Joan Merrill